These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6198082)

  • 41. Regional protection in cancer chemotherapy: an experimental study in monkeys.
    Johnson RH; Mullins FX; Schwartz SA; Perry S; Ketcham AS
    Am Surg; 1969 Oct; 35(10):741-9. PubMed ID: 4980952
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacological modulation of 5-fluorouracil and its clinical implications: an overview.
    Gebbia V; Testa A; Borsellino N; Cannata G; Valenza R; Gebbia N
    In Vivo; 1993; 7(6B):639-44. PubMed ID: 8193287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
    Tanigawa N; Mizuno Y; Hashimura T; Honda K; Satomura K; Hikasa Y; Niwa O; Sugahara T; Yoshida O; Kern DH
    Cancer Res; 1984 Jun; 44(6):2309-12. PubMed ID: 6202397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
    Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
    Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Errors involving pediatric patients receiving chemotherapy: a literature review.
    Trinkle R; Wu JK
    Med Pediatr Oncol; 1996 May; 26(5):344-51. PubMed ID: 8614368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 47. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
    Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
    Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cisplatin and related anticancer drugs: recent advances and insights.
    Barnes KR; Lippard SJ
    Met Ions Biol Syst; 2004; 42():143-77. PubMed ID: 15206102
    [No Abstract]   [Full Text] [Related]  

  • 49. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carcinogenicity of alkylating cytostatic drugs: conclusions and directions for future research.
    Kaldor J; Schmähl D
    IARC Sci Publ; 1986; (78):321-3. PubMed ID: 3583396
    [No Abstract]   [Full Text] [Related]  

  • 51. The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential.
    Yamamoto K; Nakai M; Nohara K; Yamatodani A
    Eur J Pharmacol; 2007 Jan; 554(1):34-9. PubMed ID: 17109847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The morphological and functional status of the ovaries in rats administered antitumor preparations].
    Gol'dberg ED; Borovskaia TG; Fomina TI
    Eksp Klin Farmakol; 1998; 61(6):45-7. PubMed ID: 9929817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy in alimentary tract malignomas.
    Queisser W; Heim ME
    Hepatogastroenterology; 1981 Oct; 28(5):276-83. PubMed ID: 6212524
    [No Abstract]   [Full Text] [Related]  

  • 54. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modes of resistance to antitumor agents.
    Kessel D
    In Vivo; 1994; 8(5):829-34. PubMed ID: 7727732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
    Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
    Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Current chemotherapy in neoplastic diseases. I].
    Witkowska M
    Wiad Lek; 1969 Jun; 22(12):1107-14. PubMed ID: 5805176
    [No Abstract]   [Full Text] [Related]  

  • 58. Ultrastructural changes in the dog liver cell after isolated liver perfusion with various cytotoxins.
    Merker G; Helling HJ; Krahl M; Aigner K
    Recent Results Cancer Res; 1983; 86():103-9. PubMed ID: 6685901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The cytotoxicity of Chamaenerium angustifolium (L.) Scop. and Hippophae rhamnoides L. tannins and their effect on mitochondrial respiration].
    Spiridonov NA; Arkhipov VV; Foĭgel' AG; Tolkachev ON; Sasov SA; Syrkin AB; Tolkachev VN
    Eksp Klin Farmakol; 1997; 60(4):60-3. PubMed ID: 9376762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
    Papadopoulou MV; Bloomer WD
    In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.